Our laboratory is focused on 1) understanding the genetics and molecular mechanisms that drive prostate cancer progression; and 2) elucidating mechanisms responsible for cancer drug resistance to develop novel treatment strategies for patients with advanced prostate cancer who have progressed on standard regimens. We are currently developing novel targeted therapies against metastatic castration-resistant prostate cancer (CRPC). We are embarking on new drug screening/discovery using next-generation sequencing and a matrix combination screening platform to identify potential novel drug targets and develop rationale combination therapies for CRPC.
The position involves characterizing selected drug compounds in preclinical models to help move the potential drug candidates into the clinic. The project will provide opportunities to acquire expertise in drug development from preclinical to clinical stage and advanced technologies such as 3D cell culture system, bulk and single cell RNA-sequencing, and in vitro/ex vivo/in vivo assays. We use cutting-edge cell biology and bioassay techniques to develop disease-relevant screening assays/models.
Qualifications and Job Details
Required and Preferred Skills
We are looking for a highly motivated scientist with a Ph.D., M.D., or equivalent degree and expertise in pharmacology, molecular biology, or cell biology. Strong publication record demonstrating research productivity. Ability to work independently, as well as collaboratively, within a team environment. Excellent communication and organizational skills. Candidates who are interested in innovative research using cutting-edge technologies are encouraged to apply. Cross-training between bench and clinical science will be available.
Experience in conventional cell and molecular biology techniques (e.g., western blotting, RT-PCR, cell viability assays) including mammalian cell culture and working with mouse models of cancer is a plus.
About the NCI Center for Cancer Research
The Center for Cancer Research (CCR) is home to nearly 250 basic and clinical research groups located on two campuses just outside of Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research. We collaborate with academic and commercial partners and advocacy groups across the world in efforts to prevent, diagnose and treat cancer and HIV/AIDS. The CCR research portfolio covers the full spectrum of biological and biomedical research. Our work ranges from basic to translational and clinical, and our clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research that offers a robust infrastructure to support CCR’s patients on an estimated 250 open studies. The success of CCR is grounded in an exceptionally strong discovery research program that provides the foundation for the seamless translation of insights from bench to bedside. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Bethesda is one of the most highly educated communities in the United States and has a nationally renowned school system. The city is a thriving suburban center close to Washington, D.C., and home to many restaurants, retailers and a flourishing arts and entertainment district.